Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. India
  4. NSE India Stock Exchange
  5. Cadila Healthcare Limited
  6. News
  7. Summary
    CADILAHC   INE010B01027

CADILA HEALTHCARE LIMITED

(CADILAHC)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Cadila Healthcare : India to target children for COVID-19 vaccine from Oct -sources

09/22/2021 | 01:13am EDT

NEW DELHI, Sept 22 (Reuters) - All Indian children aged 12 or older will become eligible for COVID-19 vaccinations from next month, when drug maker Cadila Healthcare launches its ZyCoV-D product, two sources with direct knowledge of the matter told Reuters.

The world's first DNA-based COVID-19 vaccine, ZyCoV-D won emergency authorisation from Indian regulators last month. From October, the company, better known as Zydus Cadila, will produce 10 million doses a month.

The health ministry did not immediately respond to a request for comment. The sources sought anonymity because they were not authorised to talk to media.

The vaccine is the only one approved for children in India, which has given a total of 825.9 million doses to adults among its population of nearly 1.4 billion. (Reporting by Neha Arora and Krishna N. Das; Editing by Clarence Fernandez)


ę Reuters 2021
All news about CADILA HEALTHCARE LIMITED
10/22CADILA HEALTHCARE : Zydus announces ‘first patient' randomised in EVIDENCES-X TM Pha..
PU
10/22Zydus Announces First Patient' Randomised in Evidences-X Phase II(B) Clinical Trial of ..
CI
10/09CADILA HEALTHCARE : Fortress Biotech and Cyprium Therapeutics Announce Positive Clinical D..
PU
10/08CADILA HEALTHCARE : Zydus Cadila receives tentative approval from USFDA for Adapalene and ..
PU
10/08CADILA HEALTHCARE : Gets US FDA's Tentative Nod for Acne Treatment Drug
MT
10/08Zydus Cadila receives tentative approval from USFDA for Adapalene and Benzoyl Peroxide ..
CI
09/24India's Shilpa Medicare to produce Cadila's COVID-19 shot
RE
09/24India's Shilpa Medicare to produce Cadila's COVID-19 shot
RE
09/24SHILPA MEDICARE : Biologics Unit Partners with Cadila Healthcare for Supply of COVID-19 Dr..
MT
09/24CADILA HEALTHCARE : Zydus Cadila receives final approval from USFDA for Apremilast Tablets
PU
More news
Financials
Sales 2022 160 B 2 140 M 2 140 M
Net income 2022 26 954 M 360 M 360 M
Net Debt 2022 24 297 M 324 M 324 M
P/E ratio 2022 23,6x
Yield 2022 0,85%
Capitalization 521 B 6 949 M 6 949 M
EV / Sales 2022 3,40x
EV / Sales 2023 3,06x
Nbr of Employees 24 412
Free-Float 25,1%
Chart CADILA HEALTHCARE LIMITED
Duration : Period :
Cadila Healthcare Limited Technical Analysis Chart | CADILAHC | INE010B01027 | MarketScreener
Technical analysis trends CADILA HEALTHCARE LIMITED
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Last Close Price 508,80 INR
Average target price 596,96 INR
Spread / Average Target 17,3%
EPS Revisions
Managers and Directors
Sharvil Pankajbhai Patel Managing Director & Executive Director
Nitin Dalsukhrai Parekh Chief Financial Officer
Pankaj Ramanbhai Patel Non-Executive Chairman
Ganesh Narayan Nayak Chief Operating Officer & Executive Director
Dhaval N. Soni Secretary & Compliance Officer